GRAIL, Inc. (NASDAQ: GRAL), a healthcare company specializing in early cancer detection, saw its stock plummet 5.03% during Friday's intraday trading session. This decline appears to be a continued reaction to the company's disappointing first-quarter 2025 financial results released earlier in the week.
The sustained sell-off follows GRAIL's after-hours plunge of 14.90% on Tuesday when the company reported its Q1 earnings. Despite posting a narrower-than-expected loss of $3.10 per share, beating analyst estimates of a $3.99 per share loss, GRAIL's revenue fell short of expectations. The company reported revenue of $31.8 million, up from $26.7 million a year earlier, but significantly below the $35.2 million forecast by analysts.
While GRAIL highlighted some positive developments, including encouraging results from its NHS-Galleri trial and a strong cash position of $677.9 million providing runway into 2028, investors seem to remain focused on the revenue miss. As GRAIL continues to develop its multi-cancer early detection tests, the market appears to be reassessing the company's near-term growth prospects, leading to the ongoing pressure on its stock price.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.